Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Fredag 16 Maj | 08:30:27 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Asarina Pharma - Two More to Go

Prenumeration

Asarina Pharma - Two More to Go

2021-03-12 08:45:00

Redeye deep-dives into the Tourette indication and includes it in our Sum of the Parts (SOTP) valuation. The inclusion of Tourette drives the increase in our Base Case. In this update, we also preview the upcoming results in Menstrual Migraine. Notably, both phase 2 studies in Tourette and Menstrual Migraine are funded.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Redeye

Bifogade filer

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden